With new gene therapies for USH in development, the findings reported here can serve as a benchmark for the comparison of novel treatments with the current clinical standard of care around the world. Larger-scale studies with more consistent monitoring of hearing and speech perception ability, as well as more extensive genetic testing, could further elucidate the benefits of current treatments for different (sub-)types of USH.
Krumpoeck et al. (Thu,) studied this question.